Strategic partnerships Immutep generates revenue through licensing and collaboration agreements, notably with Dr Reddy's Laboratories. This indicates a readiness to collaborate with pharma and biotech players for co development and commercialization opportunities.

Lead programs Lead oncology candidate eftilagimod alfa and autoimmune IMP761 position Immutep across cancer and autoimmune therapeutic areas, suggesting sales opportunities with partners seeking LAG-3 pathway platforms and first/next-in-class immunotherapies.

Clinical momentum Positive interim Phase I data presentations at EULAR for IMP761 indicate continued clinical progress, providing a compelling story for partner discussions around co development, milestone financing, and potential licensing rush opportunities.

Geographic exposure Dual listing on ASX and NASDAQ and international press coverage imply broad investor and partner visibility, facilitating outreach to global pharma companies seeking cross‑border collaboration and regional commercialization deals.

Financial signals Current revenue and a substantial funding runway (revenue $1M-$10M; funding $73M) underscore a need for alliance-driven monetization and milestone‑based partnerships to de-risk development while expanding therapeutic reach.